Press "Enter" to skip to content

Pain for big Indian pharma companies continue warns CRISIL, as FDA woes remains unresolved

The warning letter issued by the USFDA to large pharma companies more than doubled in the first 10 months of 2019 compared to 2018, CRISIl said. The impact of this is that close to 180 generic drug launches will be pushed out from its intended launch date.

Original source: